Clinical Trials Arena on MSN
InnoCare’s BTK inhibitor advances to Phase III in SLE
Within the 48-week treatment window, the Bruton’s tyrosine kinase (BTK) inhibitor triggered a 57.1% improvement in patients’ ...
Activation of certain memory B cells may be driving systemic lupus erythematosus incidence in individuals who had ...
In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...
A research team of Professor Yoontae Lee and Jiho Park, a PhD candidate, from the Department of Life Sciences at Pohang University of Science and Technology (POSTECH) recently discovered that a ...
Rituximab is a chimeric mouse–human monoclonal antibody (mAb) that targets the B-cell surface marker CD20 with high affinity. CD20 expression spans the developmental stages from the pre-B cell until ...
Please provide your email address to receive an email when new articles are posted on . Last November, at the American College of Rheumatology Convergence 2023, several faculty members presented new ...
Dr. Hui-Chen Hsu is Associate Professor of Medicine in the Division of Clinical Immunology and Rheumatology. Dr. Hsu collaborated with Drs. John D. Mountz, Hao Li, Jun Li, Yong Zhou, David Crossman, ...
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...
Zenas BioPharma (ZBIO) announced that its partner, InnoCare Pharma (INCPF) announced the achievement of the primary endpoint in a Phase 2b study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback